New study aims to unlock immune secrets of nasopharyngeal cancer
NCT ID NCT07198802
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will look at tissue samples from 600 people with nasopharyngeal carcinoma to understand how the tumor's immune environment changes over time. The goal is to find markers that predict how well immunotherapy will work and to identify new treatment targets. Participants must be between 15 and 75 years old and have received combined therapy at the study hospital.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with nasopharyngeal carcinoma who were admitted to our hospital
- Ages
-
15 to 75 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria Before the trial, the participants must meet all of the following requirements to be eligible for inclusion. 1. Clearly diagnosed with nasopharyngeal carcinoma by pathology; 2. Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital; 3. Patients diagnosed in our hospital from January 2025 to December 2028; 4. Have relatively complete clinical data; 5. Age between 15 and 75 years old; Exclusion Criteria Before the trial, the participants who meet any of the following requirements cannot be included. 1. The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.; 2. The participants failed to obtain pathological and imaging data for various reasons; 3. Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood test model flag dangerous myelosuppression before it strikes?
- Experimental infusion drug tested against recurrent nasopharyngeal cancer
- DNA blood test may spot nasopharyngeal cancer earlier than current methods
- Million-Person quest to catch a silent cancer early
- Can a new drug combo shrink High-Risk throat tumors?
- Can a lower radiation dose still beat nasopharyngeal cancer?